Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global artemisinin market is expected to register a revenue CAGR of 7.3% during the forecast period.

Artemisinin Market Fundamentals 

Artemisinin is a sesquiterpene lactone derived from the ancient Chinese medicinal plant Artemisia annua. It has an endoperoxide bridge, distinguishing it from other first-generation antimalarial medicines. Artemisinin and its derivative medications have benefited humanity over the past two and a half decades after its discovery as a potential antimalarial. Artemisinin-based combination therapy (ACT) is currently recommended for treating P. falciparum malaria. Fast-acting artemisinin-based compounds are coupled with medication from a different class. Lumifantrine, mefloquine, amodiaquine, sulfadoxine/pyrimethamine, piperaquine, and chlorproguanil/dapsone are examples of companion medications. Artemisinin derivatives include dihydroartemisinin, artesunate, and artemether.

This substance and its derivatives are most commonly used to treat malaria and parasitic worm infections because they have an advantage over other treatments. They can kill parasites faster and at all stages of their life cycle. The World Health Organization (WHO) recommends this drug as first-line therapy for all instances of malaria, making it a recommended treatment choice for hospitals and healthcare facilities. Artemisinin and its derivatives kill parasites swiftly and eliminate them from the body, providing residual protection against reinfection. Compared to standard treatment, ACT treatment of patients admitted to hospitals with imported uncomplicated jungle fever resulted in faster parasite clearance with lower severity in patients.

Increasing research into the substance's application in cancer therapies will likely drive market growth throughout the forecast period. It can be used as an alternative to more aggressive cancer therapy since, unlike other methods, it does not allow cancer cells to develop resistance to it. Furthermore, it is a non-toxic drug that is not harmful even when used repeatedly. It is also affordable and simple to deliver, which may boost its availability to many cancer cases worldwide. It slows cancer progression and encourages cancer cells to self-destruct while cutting off their blood supply to provide promising outcomes.

However, the continued use of oral artemisinin-based monotherapies is thought to be a primary contributor to the development of artemisinin derivative resistance. WHO urges regulatory authorities in malaria-endemic countries to take action to prohibit the manufacturing and sale of these oral monotherapies and increase access to high-quality artemisinin-based combination treatments (ACTs). ACTs are the basis of prescribed antimalarial therapies. Their efficacy must be maintained because no new class of antimalarial medications is projected to enter the market in the coming years.

Artemisinin Market Dynamics 

The global artemisinin market is predicted to increase significantly over the forecast period due to its expanding application breadth in the pharmaceutical sector. Following WHO's recognition of artemisinin-based combination therapy (ACT) as a first-line treatment for malaria, demand for artemisinin has increased dramatically over the last decade. A rise in R&D activities and expanding medical infrastructure, particularly in rising nations such as China and India, has fueled demand for artemisinin and its derivatives. Rising demand from malaria-endemic nations such as Congo, Nigeria, Tanzania, Uganda, and other South-East Asian countries such as India is predicted to boost the market for artemisinin and its derivatives in the coming years.

Other factors that drive market growth include public awareness campaigns and other government initiatives. For example, in July 2022, India's Ministry of Health and Family Welfare began Jan Abhiyaans with log bhagidari (people's involvement) to excite and engage residents and communities in ensuring mosquito-free houses, businesses, and neighborhoods. Similarly, WHO established the E-2025 program in July 2021 to help 25 countries and one territory recognized as having the ability to eliminate malaria by 2025. As a result, such activities are anticipated to boost market growth.

The product's increased demand for malaria therapy due to its antibacterial, antifungal, antileishmanial, antioxidant, anticancer, and anti-inflammatory qualities drive market revenue growth. This is a powerful medicine known for its ability to rapidly reduce the quantity of plasmodium parasites in the blood of malaria patients, aiding in treating the condition. Combined therapies with the drug reduce the number of parasites during the first three days of therapy for uncomplicated P. falciparum jungle fever and chloroquine-resistant P. vivax jungle fever. Furthermore, rising malaria infectivity increases hospital use, driving revenue growth during the forecast period.   

Poor pharmacokinetic properties of the product, such as absorption, distribution, and excretion from the body, may impede market expansion throughout the projection period due to lower product usage. Due to low bioavailability, short in vivo half-life, poor water solubility, and toxicity with long-term use, their pharmacological limitations limit market revenue growth. Their current formulation is more expensive than other antimalarials for treating jungle fever, resulting in fewer applications. Furthermore, the substance's utility is limited by aggregation during storage, burst drug release effects, and the vulnerability of selected drug linkers to certain enzymes, resulting in fast drug release, which limits market revenue growth during the forecast period.

Artemisinin Market Ecosystem 

The global artemisinin market is analyzed from the following perspectives by product type, application, and region.

Artemisinin Market by Product Type

[75675]

Based on the product types, the global artemisinin market is segmented into extracted from artemisia annua and semisynthetic artemisinin. 

The artemisia annua segment is expected to register significant revenue growth during the forecast period due to its antimalarial properties, which propel its use to treat multidrug-resistant forms of falciparum jungle fever. It is an organic peroxide and a sesquiterpene lactone that acts as an antimalarial and a plant metabolite, effectively treating malaria and reducing fever and edema. Annua extracts in water, methanol, ethanol, or acetone have anti-inflammatory, antioxidant, and antibacterial properties useful in medical and dental treatments. Because of the related drawbacks of abdominal discomfort, the prevalence of carcinogenic qualities, and the cost ineffectiveness of continuous use, the drug is recommended above other oral treatments with anti-inflammatory effects. Furthermore, lower-cost medicinal benefits are increasing demand and driving market revenue growth.

Artemisinin Market by Application

Based on the applications, the global artemisinin market is segmented into antimalarial injections and antimalarial tablets. 

Due to the rapid injection of the medicine for faster relief, the antimalarial injections market will likely exhibit considerable revenue increase during the projection period. Severe malaria can cause pulmonary edema, acute renal failure, severe anemia, and bleeding, leading to metabolic problems such as acidosis and hypoglycemia, which can quickly lead to death, making it critical to provide immediate treatment with antimalarial medicines administered intravenously (IV) for faster absorption. Furthermore, FDA approval of antimalarial injections expands their use in cases of severe infection.

This medicine requires less frequent administration, making it an important tool for jungle fever management and eradication. Tiny compounds can be created for injection as natural molecules or pro-drugs that provide at least two months of protection, reducing the need for frequent administration, particularly in impoverished and disease-ridden areas. Furthermore, a single injection protects for several months at a low cost, resulting in revenue growth.

Artemisinin Market by Region

Based on the regions, the global artemisinin market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

The Asia Pacific region is predicted to have considerable revenue growth throughout the forecast period, owing to the rising use of local medicines in this region. According to data from the Organization for Economic Cooperation and Development, this region contains around 2.31 billion individuals at high risk of malaria infection, boosting product consumption. A report published in The Lancet on March 2022 offered a combination therapy based on three artemisinins for jungle fever to combat antimalarial drug resistance, increasing R&D and driving market revenue growth in this region.

Due to the highest cancer prevalence in this region, the North American region is predicted to contribute to a consistent revenue CAGR during the projection period. Artemisinin drug repurposing for anticancer medicines is gaining popularity, increasing demand for the commodity. This medicine has been proven to have significant anticancer benefits in a range of malignancies, with combination effectiveness against various tumor types, including breast, prostate, and ovarian cancer, boosting its demand. Furthermore, it can influence various signaling pathways and function on many targets. It is well tolerated and safe at low dosages with a low risk of severe toxicity. It is expected to increase demand for the commodity in this region over the forecast period.     

Artemisinin Competitive Landscape

Some of the prominent market players in the global artemisinin market include,

• Sanofi S.A.
• Guilin Pharmaceutical Co., Ltd.
• Novartis International AG 
• KPC Pharmaceuticals
• BIONEXX
• Novanat Bioresource
• Kerui Nanhai
• Guangxi Xiancaotang 
• CAT KHANH
• BEEPZ

Artemisinin Strategic Development 

• In April 2023, Fosun Pharma produced innovative artemisinin-based antimalarial drugs contributing to the Belt and Road Initiative's efforts to eradicate malaria.
• In April 2023, the global campaign against malaria reached an important turning point in Africa on World Malaria Day 2023. Malaria parasites resistant to artemisinin have appeared in Rwanda, Uganda, and the Horn of Africa. There is no rapid successor for artemisinin-based combination treatments (ACTs), the first-line therapy for malaria. Millions of Africans, especially children under five, will be in danger of drug-resistant malaria infection and death if ACTs are no longer available.
• In August 2022, the Bill & Melinda Gates Foundation awarded Manus Bio its fourth grant to create a scalable manufacturing pathway for artemisinin, a potential antimalarial medication. The USD 2 million prize would allow Manus Bio to begin scaling up its unique biological approach towards the critical chemical intermediate, dihydroartemisinic acid.
• In July 2022, India successfully cultivated artemisia to generate artemisinin (drug) and its derivatives for treating acute malaria and parasitic worm (helminth) infections.
• On September 2021, Novartis International AG and Medicines for Malaria Venture reported Phase 2b study findings for a novel non-artemisinin combination for uncomplicated malaria therapy. Ganaplacide, a new medication with an entirely different mechanism of action, was investigated for treating malaria infection, including artemisinin-resistant strains, and preventing malaria parasite transmission. It will assist the firm in the development of next-generation antimalarials.

Frequently Asked Questions About This Report